Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Hebei Senlang Biotechnology

Request full access

Focused on the treatment of immune cells new technology development and application of high-tech enterprises

Baoding, ChinaFounded 2016Biotech & Life Sciences

About Hebei Senlang Biotechnology

Hebei Senlang Biotechnology, established in January 2016, is a biopharmaceutical company focused on the development and application of cell therapy technologies for the precise treatment of malignant tumors. The firm was co-founded by Dr. Li Jianqiang, who serves as the chairman and chief scientist. Dr. Li brings extensive overseas research and development experience, having held senior scientist positions at renowned institutions like the City of Hope National Medical Center and the Fred Hutchinson Cancer Research Center. This background in cellular immunology has been foundational to the company's direction.

The company operates in the competitive field of immuno-oncology, developing CAR-T cell therapies for both hematologic cancers and solid tumors. Its business model encompasses the entire lifecycle from initial research and development to clinical trials and eventual commercialization. Revenue generation appears structured around the development and subsequent out-licensing or commercial sale of its therapeutic products. A key milestone was the May 2022 completion of a 200 million RMB C-round financing led by Qianhai FOF, aimed at advancing its product pipeline and upgrading technology platforms. In June 2021, Avalon GloboCare announced a definitive agreement to acquire SenlangBio in an all-stock transaction, though the current status of this acquisition is not detailed.

SenlangBio has developed a comprehensive pipeline of cell therapies. Its core technology platforms include autologous CAR-T/TCR-T cells, universal CAR-GDT cells, and CAR-HSPC-NK technologies. One of its leading products, an anti-CD19 CAR-T therapy (Senl_1904B) for B-cell acute lymphoblastic leukemia, received Investigational New Drug (IND) approval from China's NMPA to begin Phase I trials in 2021 after demonstrating a 97.2% complete remission rate in investigator-initiated trials. Another key candidate is the SENL101 autologous T-cell injection, a CAR-T product targeting CD7 for T-cell acute lymphoblastic leukemia/lymphoma, which has received Orphan Drug Designation from the U.S. FDA. The company has established a 14,000-square-meter R&D and production base, enabling an integrated process from vector production to cell preparation, and collaborates with numerous hospitals for clinical research.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
6
Dealroom signal
24.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC May 2022 $28M $138M Qianhai FOF ↗
SERIES B✓Equity / VC Dec 2018 $0 — Undisclosed ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Hebei Senlang Biotechnology website traffic

Latest recorded traffic for Hebei Senlang Biotechnology is 610 monthly website visits, down 49.2% over the last three months. Hebei Senlang Biotechnology's team grew 0% over the past year.

Latest monthly visits610 3-month web change-49.2% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Hebei Senlang Biotechnology in the Baoding ecosystem

Live from Dealroom

The Hebei Senlang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Qianhai FOF
Employees 2 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Baoding HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Hebei Senlang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Hebei Senlang Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.